Looks back at real-world prostate cancer treatment experiences in patients worldwide
Reviews past records of men with metastatic prostate cancer and their treatments.
Plain-language title generated from the registry record
Registry title: ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Key facts
- Where
- Province of Macerata, ItalySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study looks at past treatment records of adults with metastatic prostate cancer. It covers three groups: hormone-sensitive cancer, Lutetium-177 PSMA treatment, and PARP inhibitor treatment.
- Age
- Older than 18 years
- Sex
- All sexes
- Disease stage
- Metastatic prostate cancer, confirmed by tissue tests or imaging. Castration-resistant for the Lutetium-177 PSMA and PARP inhibitor groups.
- Earlier treatment
- Must have been treated with one of the listed regimens. For example ADT plus apalutamide, enzalutamide, abiraterone or darolutamide (some with docetaxel), Lutetium-177-PSMA, or a PARP inhibitor such as olaparib.
- Biomarker or test result
- For the PARP inhibitor group, HRD positive status is needed.
Main reasons for not taking part
- No tissue-confirmed prostate cancer
- No metastatic disease confirmed by tissue tests or imaging
- Treated with drug combinations not on the study list
- Lutetium-177-PSMA given for hormone-sensitive or castration-sensitive cancer
- HRD negative status in the PARP inhibitor group
Read by machine on 12 November 2026.
Where in Italy
- Ospedale Di MacerataProvince of Macerata, ItalyContact: Matteo Santoni, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital of Macerata
- Trial code
- NCT06200558
- Record updated
- 26 November 2025
- Original description
Study wants to explore real-world data in three distinct settingsRead full original descriptionShow less
ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Study wants to explore real-world data in three distinct settings
* Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel _ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC _ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC _ ARON-3GEN
Inclusion: Patients aged >18y; Cytological or Histologically confirmed diagnosis of PC; Histologically or radiologically confirmed diagnosis of metastatic disease and; For ARON-3S; ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible); For ARON-3Lu; ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC; For ARON-3GEN; HRD POSITIVE STATUS; Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide.
Exclusion: Patients without histologically or radiologically confirmed metastatic disease and; For ARON-3S; ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section; For ARON-3Lu; ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC; For ARON-3GEN; Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study; Patients without histologically confirmed diagnosis of PC; HRD NEGATIVE STATUS.